On December 30, GELONGHUI reported that Aurora Mobile-B (06681.HK) announced that the company plans to globally offer approximately 0.181 billion shares, with 18.112 million shares available for sale in Hong Kong and 0.163 billion shares for international sale, along with an over-allotment option of 15%; the subscription period will be from December 30, 2024, to January 3, 2025; the offering price will be HKD 3.22 per share, with a minimum trading unit of 1,000 shares. China International Capital Corporation and Puyi International are the joint sponsors; it is expected that the shares will begin trading on the Stock Exchange on January 8, 2025.

The company was established in 2012. Its product pipeline covers a wide range of cognitive impairments caused by vascular diseases, neurodegenerative diseases, mental illnesses, and developmental disabilities in children. As of the last practicable date, the company's core product—a Brain Function Information Management Platform Software System—has been commercialized for eight indications across four main types of cognitive impairments, and the company is developing several other cognitive impairment indications. As of the last practicable date, three additional products have received regulatory approval in China (namely Basic Cognitive Ability Test Software ("BCAT"), Cognitive Ability Auxiliary Screening Assessment Software ("SAS"), and Dyslexia Auxiliary Screening Assessment Software ("DSS")), and one product has received regulatory approval in the European Union (namely Cognitive Dysfunction Treatment Software), with six candidate products in various stages of preclinical and clinical development or registration processes. The company holds rights to its products and candidate products in the jurisdictions where it has obtained regulatory approval.

The company has entered into cornerstone investment agreements, under which cornerstone investors have agreed to subscribe for a certain number of offered shares at the offering price. Assuming the offering price is HKD 3.22, the total number of shares to be subscribed by the cornerstone investors will be approximately 0.116 billion shares, accounting for about 64.27% of the total shares offered in the global offering and 9.19% of the shares issued after the subdivision and completion of the global offering (assuming the over-allotment option is not exercised). Cornerstone investors include Tasly Pharmaceutical Group (Hong Kong) Co., Ltd. ("Tasly (Hong Kong)", which is wholly owned by Tasly (600535.SH) indirectly), Tasly (International) Medical Health Investment Development Co., Ltd. ("Tasly (International)", which is wholly owned indirectly by Tasly Biomedical Industry Group Co., Ltd. through its wholly-owned subsidiary Tianjin Tasly Medical Health Investment Co., Ltd.), Mr. Huang Guangwei, and Suzhou Ciyuan Fuhai Enterprise Management Partnership (Limited Partnership) ("Suzhou Ciyuan").

Assuming the over-allotment option is not exercised, at an offering price of HKD 3.22 per share, the company estimates that it will receive net proceeds of approximately HKD 0.5013 billion from the global offering. Of this net proceeds, approximately 40.0% is expected to be used for further R&D activities, advancing more clinical trials for additional indications, and promoting sales and distribution activities for the core product system; approximately 16.5% is expected to be used to help more hospitals in China establish new cognitive centers, where hospitals can use the company's products to diagnose and treat patients with cognitive impairments and/or other conditions; approximately 15.0% is expected to be used to enhance the company's AI and related technology capabilities over the next two years; approximately 5.0% is expected to be used to accelerate the R&D and commercialization progress of other candidate products inside and outside the current product pipeline, with priority given to developing indications with broad prospects; approximately 15.0% is expected to be used to collaborate with academic institutions and hospitals to establish brain science and digital therapy research centers over the next two years, prioritizing cooperation projects likely to bring recent benefits to the company's R&D progress; and approximately 8.5% is expected to be allocated as the company's working capital and for other general corporate purposes.